Michael Soth

Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders

David Goldstein, A. Kuglstatter, Yan Lou et al. · Journal of Medicinal Chemistry · 2009 · 180 citations · Full text

Lung Inflammation, Immunology, Altmetric Attention Score +16

Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis

Yan Lou, Xiaochun Han, A. Kuglstatter et al. · Journal of Medicinal Chemistry · 2014 · 106 citations

Pharmaceutical Science, Tyrosine Kinase, Immunology +18

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

Michael Soth, Kang Le, Maria Emilia Di Francesco et al. · Journal of Medicinal Chemistry · 2020 · 88 citations · Full text

Discovery of 6-(2,4-Difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidin-7-one (Pamapimod) and 6-(2,4-Difluorophenoxy)-8-methyl-2-(tetrahydro-2<i>H</i>-pyran-4-ylamino)pyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-one (R1487) as Orally Bioavailable and Highly Selective Inhibitors of p38α Mitogen-Activated Protein Kinase

David Goldstein, Michael Soth, Tobias Gabriel et al. · Journal of Medicinal Chemistry · 2011 · 74 citations · Full text

Pharmacotherapy, New Series, System Pharmacology +21

3-Amido Pyrrolopyrazine JAK Kinase Inhibitors: Development of a JAK3 vs JAK1 Selective Inhibitor and Evaluation in Cellular and in Vivo Models

Michael Soth, Johannes C. Hermann, Calvin Yee et al. · Journal of Medicinal Chemistry · 2012 · 66 citations · Full text

Drug Target, Janus Kinases, Immunology +21